| 20.07 Data as of Mar 07 |  +0.53 / +2.71%Today’s Change | 15.39 Today|||52-Week Range 24.10 | +3.45% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $842.9M |
Company Description
Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. It operates its business through two segments: Technology & Strategic Partnerships, and Assays & Related Products. The Technology and Strategic Partnerships segment licenses the company's xMAP technology to its partners, who then develop products that incorporate the xMAP technology into products that they sell to end users. It also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells these products to its partners. The Assays and Related Products segment is primarily involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. This segment focuses on multiplexed applications for the human molecular clinical diagnostics market. Its products are focused on the three segments of the genetic testing market: Human Genetics, Personalized Medicine, and Infectious Disease. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.
Employees
Shareholders
| Mutual fund holders | 38.95% |
| Other institutional | 33.25% |
| Individual stakeholders | 13.46% |
Top Executives
| Patrick J. Balthrop | President, Chief Executive Officer & Director |
| Michael F. Pintek | Senior Vice President-Operations |
| Harriss T. Currie | Chief Financial Officer, Treasurer & VP |
| Thomas J. Copa | Vice President-Luminex Life Sciences |
| Charles J. Collins | Vice President-Systems Research & Development |
.
